Gemcitabine, Docetaxel a Viable Alternative to BCG in Bladder Cancer

MONDAY, March 13, 2023 (HealthDay News) -- For patients with non-muscle invasive bladder cancer (NMIBC), gemcitabine and docetaxel therapy is associated with less high-grade disease recurrence, according to a study published online Feb. 28 in JAMA Network Open.
Ian M. McElree, from the University of Iowa in Iowa City, and colleagues compared outcomes of patients with high-risk NMIBC treated with gemcitabine and docetaxel versus bacillus Calmette-Guérin (BCG). Data were included for 312 patients with high-risk treatment-naive NMIBC: 174 and 138 treated with BCG therapy and with gemcitabine and docetaxel therapy, respectively.
The researchers found that the high-grade recurrence-free survival (RFS) estimates were 76, 71, and 69 percent, respectively, at six, 12, and 24 months in the BCG group and 92, 85, and 81 percent, respectively, in the gemcitabine and docetaxel group. Treatment with gemcitabine and docetaxel was associated with better high-grade RFS and RFS than BCG in analyses controlling for age, sex, treatment year, and presence of carcinoma in situ (hazard ratios, 0.57 and 0.56, respectively). Greater treatment discontinuation was seen for induction therapy for BCG versus induction therapy for gemcitabine and docetaxel (9.2 versus 2.9 percent).
"The findings of this study support the use of gemcitabine and docetaxel for the treatment of high-risk NMIBC, suggesting that this regimen can be considered for recommendation in updated practice guidelines," the authors write. "Further prospective evaluation is needed."
One author disclosed financial ties to the pharmaceutical industry.
Related Posts
In Good News for U.S., Flu Vaccine Working Well in South America
MONDAY, Sept. 11, 2023 (HealthDay News) – In a finding that should ease the...
Severe Bleeding: What to Do for Your Child
What should I do if my child is bleeding badly?You'll need to act quickly. If...
FDA Approves Talzenna for Metastatic, Castration-Resistant Prostate Cancer
MONDAY, June 26, 2023 (HealthDay News) -- The U.S. Food and Drug Administration...
Soaring Misuse of Horse Tranquilizer Xylazine Is Worsening Opioid Crisis
FRIDAY, June 30, 2023 (HealthDay News) -- Drug overdose deaths involving a...